The core pillars of the life sciences and healthcare offering at A&O Shearman are transactional work, IP litigation and regulatory advice. Additional areas of strength include antitrust, employment and investigations. Practice co-head Jim Ford has developed a market reputation for advising on matters at the cutting edge such as the use of AI and machine learning in the drug development process. Fellow co-head Matthew Appleton excels in transactional mandates encompassing cross-border brand divestitures, strategic collaborations, acquisitions, and sales. Marjan Noor excels in life sciences patent litigation and frequently handles both enforcement and defence on behalf of patent holders. Rafi Allos‘ contentious expertise incorporates litigation against generics. Cross-border transactional work involving the development and exploitation of IP is a mainstay of Megan McMellon‘s practice.
Life sciences and healthcare in London
A&O Shearman
Responsables de la pratique:
Jim Ford
Autres avocats clés:
Marjan Noor; Rafi Allos; Mark Ridgway; Nigel Parker; f Megan McMellon; Gemma Barrett; Alex Shandro; Tom Edwards; Erin Currie
Les références
‘Allen & Overy has global reach and resources to apply to issues.’
‘Jim Ford has a strong knowledge of commercial agreements in the pharma industry and a pragmatic approach to problem solving.’
‘A&O Shearman London is one of the top practices in the UK Life Sciences and healthcare market. The size and breadth of the team is excellent, particularly the quality of the talent.’
Principaux clients
Exscientia
Haleon
Kwoya Kirin International
Shionogi
Bayer
GSK
Grünenthal
Life Healthcare
Exponent Private Equity
Reckitt
Principaux dossiers
- Retained by Exscientia to advise on its strategic AI-drug discovery collaborations including advising on its USD674 million AI drug discovery collaboration with Merck KGaA
- Advising Bayer on the enforcement and defence of its patents across Europe protecting Xarelto®, its highest-selling product.
- Advised Haleon on the divestiture of its Lamisil brand across 70+ jurisdictions to Karo Healthcare AB
Bird & Bird LLP
Praised for its ‘superb knowledge of the industry’ Bird & Bird LLP handles a wide range of work including IP, regulatory, transactional, and commercial law mandates. Mark Hilton co-heads the practice alongside Brussels-based IP expert Marc Martens. Hilton specialises in patent litigation and is active across areas such as high-value patent revocation and infringement proceedings and damages enquiries. Sally Shorthose is well-placed to guide life sciences clients through licensing, partnering and exploitation agreements. Morag Macdonald and Eleanor Root further extend the patent litigation expertise at the firm, while corporate specialist James Baillieu‘s expertise extends to venture capital financings and exits. Qualified barrister Chris De Mauny is a key member of the firm’s international patent group. Pieter Erasmus excels in regulatory matters relating to digital health and medical devices.
Responsables de la pratique:
Mark Hilton; Marc Martens
Autres avocats clés:
Sally Shorthose; Morag Macdonald; Eleanor Root; James Baillieu; Chris De Mauny; Henry Elliott; Patrick Brown; . Pieter Erasmus; Sophie Vo;
Les références
‘Excellent experience, give good commercial advice.’
‘Superb knowledge of the industry. In-depth knowledge of the sector and a solid understanding of the regulatory framework.’
Principaux clients
Dexcom
CureVac
The Broad Institute
Merck KGaA
Celltrion
Convatec
Gilead Sciences
Teva
Alvotech
WS Audiology
Principaux dossiers
- Acting for Dexcom, in multiple international patent infringement and revocation claims against Abbott in relation to their glucose monitoring devices.
- Acted for the Dementia Discovery Fund (DDF) and LifeArc on their £9.25 M Series A investment into Cumulus Neuroscience Limited, a digital health company focused on advancing neuroscience clinical trials and patient care through improved data.
- Acting for CureVac in patent revocation and infringement proceedings in the UK against BioNTech and Pfizer, and in parallel German infringement proceedings against BioNTech, in relation to their patents in the field of mRNA vaccines.
Bristows LLP
From the establishment and financing of pioneering life sciences companies to patent litigation and complex IP issues relating to projects and collaborations concerning products and services driven by AI technology, Bristows LLP is active across a wide range of work in the life sciences space. Practice co-head Liz Cohen is a seasoned patent litigator with a proven track record in co-ordinating cross-border litigation. Fellow co-head Richard Dickinson is equipped to assist clients with manufacturing and supply agreements. ‘Standout‘ partner Brian Cordery is active across patent disputes for medicines used to treat conditions such as multiple sclerosis, leukaemia and heart failure, while Alex Denoon‘s regulatory expertise is sought after by clients specialising in disruptive technologies. Robert Burrows‘ expertise extends to plant variety right cases for clients in the life sciences sector, and Claire Smith advises on a range of commercial partnering agreements. Adrian Chew further extends the patent disputes expertise at the firm.
Responsables de la pratique:
Liz Cohen; Richard Dickinson
Autres avocats clés:
Brian Cordery; Robert Burrows; Greg Bacon; Rachel Mumby; Matthew Warren; Marek Petecki; Claire Smith; Alex Denoon; David Horner; Xisca Borrás; Ellen Lambrix; Charlie French; Nick Cross; Claire Phipps-Jones; Adrian Chew; Chloe Dickson; Chris Stubbs
Les références
‘The Bristows team are a team to be reckoned with in the fields of life sciences and healthcare. They combine excellent technical knowledge with legal nous to achieve the commercial objectives of their clients, guiding them efficiently and effectively to a valuable result. ’
‘Charlie French is excellent to work with, intelligent and responsive, manages the team effectively with ease.’
‘Chloe Dickson is a very bright senior associate who will go far: intelligent and commercial.’
Principaux clients
Syncona
Telix Pharmaceuticals
Bestway Panacea Holdings Limited
Novartis Pharmaceuticals
Sandoz
Teva Pharmaceutical Industries
Mara Renewables
Genentech
Touchlight
AstraZeneca
LifeArc
Recordati
Google DeepMind
GlaxoSmithKline (GSK)
OMass Therapeutics Limited
Norgine
Amgen
Johnson & Johnson / Janssen Pharmaceutica NV
UCL Business
Medtronic
Oxford Science Enterprises
Royal Pharmaceutical Society
Ultromics
The Wellcome Sanger Institute
Principaux dossiers
- Advised AstraZeneca on a high profile patent deal with Chinese biotech Usynova to add to AstraZeneca’s oncology pipeline by licensing Usynova’s novel pancreatic cancer therapy in a transaction worth $420 million.
- Acting for Genentech and Novartis in ongoing UK High Court revocation and infringement proceedings against Celltrion in respect of Genentech’s and Novartis’s antibody medicine Xolair (ex-US sales $1.463 billion).
- Advising Syncona on the establishment and financing of ophthalmic gene therapy company Beacon Therapeutics, which launched in June 2023 following a £96 million Series A financing.
Covington & Burling LLP
A range of pharmaceuticals, biotechnology companies and medical device manufacturers turn to Covington & Burling LLP for assistance with work including strategic transactions, M&A, fundraising, post-Brexit divergence and issues related to digital health. Grant Castle heads up the team. His far-reaching practice incorporates GXP-related advice to pharma companies, including in relation to pharmacovigilance and manufacturing issues. Solicitor advocate Brian Kelly represents a range of pharmaceutical clients before English courts and EU Courts. Sarah Cowlishaw is noted in the market for her expertise pertaining to digital health. Daniel Pavin has developed a market reputation for handling collaborations and commercial agreements in the life sciences sector. Winsome Cheung is well-placed to guide pharmaceutical companies and innovative biotechnology companies through the intricacies of strategic partnering arrangements, while Raj Gathani is a popular contact for clients looking to launch new medicines, devices and digital health products into the UK market.
Responsables de la pratique:
Grant Castle
Autres avocats clés:
Brian Kelly; Sarah Cowlishaw; Robin Blaney; Paul Claydon; James Gubbins; Lucinda Osborne; Daniel Pavin; James Halstead; Gregor Frizzell; Winsome Cheung; Raj Gathani
Principaux clients
AMGEN
AbbVie
AstraZeneca
Autifony Therapeutics
BenevolentAI
BioNTech SE
Boehringer Ingelheim Corporation
Bristol Myers Squibb
Destiny Pharma PLC
Eli Lilly
Ergomed plc
GlaxoSmithKline
Health Data Research UK
Illumina, Inc.
Insmed Incorporated
Johnson & Johnson
Merck Sharp & Dohme
Novartis
Oxford BioMedica plc
Oxford Immunotec Global plc
QuantuMDx Group Ltd
Reneuron Group plc
Silence Therapeutics Plc
Takeda
UCB, Inc.
Viiv
Abingworth
Agrobio SAS
Monograph Capital
Sitryx Therapeutics
Revolov Biotherapeutics Limited
Hogan Lovells International LLP
Hogan Lovells International LLP far-reaching practice encompasses expertise in areas including intellectual property, product liability and commercial litigation, regulatory and licensing. A trio of partners oversee matters: Stephen Bennett’s proficiency in contentious patent matters has made him a key contact for pharmaceutical companies. Matthew Felwick is well-placed to handle sensitive mandates such as coroners’ inquests following unexpected deaths. Jane Summerfield is frequently tasked with advising on the regulatory aspects of clinical trials, product authorisation and supply chain licensing. Further recommended are Penny Powell, who frequently guides clients through corporate and commercial deals in the life sciences, healthcare and technology sectors, and Stella Wong who excels in multi-jurisdictional patent litigation.
Responsables de la pratique:
Stephen Bennett; Matthew Felwick; Jane Summerfield
Autres avocats clés:
Penny Powell; Stella Wong
Principaux clients
Sandoz AG
Molecular Partners AG
Novartis AG
Adalvo Group
Eli Lilly (Lilly)
Bristol Myers Squibb (BMS)
Akebia Therapeutics
Astellas Pharmaceuticals
Viatris
Zimmer Biomet
Principaux dossiers
- Advised Molecular Partners AG on its research, development, manufacturing and commercialisation collaboration with Orano Med (a pioneer in targeted alpha therapy) to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells.
- Representing Astellas in litigation relating to its Betmiga product in the UK as part of its global litigation to maintain patent protection.
- Acting for Zimmer Biomet and various European subsidiaries in relation to a voluntary recall, concerning Zimmer Biomet’s NexGen Stemmed Option Tibial prosthetic knee component, and coordinating the defence of personal injury claims, including a threatened group action, across a number of European jurisdictions.
Pinsent Masons LLP
Core pillars of the practice at Pinsent Masons LLP include patent and supplementary protection certificate (SPC) strategic advice and litigation; transactions including, asset purchases & sales, corporate financing and licensing; and advice across a range of UK and EU competition issues. Charlotte Weekes heads up the life sciences team and is well-versed in contentious patent work, notably in matters involving generics and biosimilars. Joanne Ellis heads up the healthcare offering from the firm’s Birmingham office. She frequently handles private company and private equity work in the sector including investments, refinancings and disposals. Gareth Morgan is noted by peers in the market for his expertise in IP trials concerning patent entitlement and the interpretation of IP licences. Patent litigator Christopher Sharp frequently acts in cases in courts ranging from the Patents Court to the Court of Appeal, and the Supreme Court. Allistair Booth is praised for his ability to structure ‘nuanced, complex and productive deals across biotech’.
Responsables de la pratique:
Joanne Ellis; Charlotte Weekes
Autres avocats clés:
Kristina Cornish; Gareth Morgan; Christopher Sharp; Cerys Wyn Davies; Allistair Booth; Tracey Roberts; Jacqueline Harris; Robert Vidal; Gina Bicknell; Anna Harley; Kiah York; Alasdhair McDonald; Carissa Kendall-Windless
Les références
‘The team at Pinsent Masons have had a couple of standout years; involved in practically all the major pieces of litigation even to the extent that they appeared in trials for more than one party (with appropriate information barriers). Very impressive.’
‘Chris Sharp is a standout partner. Busy, client-focused, really good and experienced; arguably the ‘partner of the year’ in this area. Other key partners are Charlotte Weekes, Gareth Morgan and Tracey Roberts. Key associates are: Anna Harley, Carissa Kendall-Windless. They also have a team of really helpful and user-friendly paralegals.’
‘Dedicated and client-orientated team.’
Principaux clients
Teva Pharmaceutical Industries Ltd.
Accord Healthcare Limited
Sandoz
Fresenius Kabi Swiss BioSim and local entities
Kuano AI
ACD
Flynn Pharma [Limited]
Istesso Limited
Oncimmune
Midlands Mindforge
The Cabinet Office – HM Government
The Department of Health & Social Care, HM Government
Secretary of State for Health & Social Care
Elevation Advisors LLP
The Orders of St. John Care Trust
AcalisCare
Principaux dossiers
- Representing Teva in proceedings against BMS in multiple jurisdictions, including the UK, in relation to the blockbuster anti-coagulant drug Eliquis (apixaban) for more than 3 years.
- Acting for Flynn Pharma on groundbreaking litigation in the UK relating to its flagship product, Circadin.
- Advising the Cabinet Office in its response to each of the various modules of the Covid Inquiry, relating to, amongst other areas, ‘resilience and preparedness’ and ‘core UK decision-making and political governance’. Also acting for the Department of Health and Social Care in respect to the same Inquiry.
Arnold & Porter
Praised for its ‘meticulous attention to detail’, Arnold & Porter is noted on the market for its strength in regulatory and life sciences product liability mandates and is additionally well-placed to handle patent litigation, transactional and cannabis investment work. Practice head Adela Williams possesses extensive experience in providing regulatory advice for clinical trials, marketing authorisations, and medical devices across the UK and the EU, and frequently acts in product liability disputes. Jacqueline Mulryne advises on borderline classification, market access strategy and cross-border regulatory compliance mandates. Beatriz San Martin often appears before the CJEU and domestic courts in IP disputes and is well-versed in issues connected with synthetic biology, digital health and cell and gene therapies. Ewan Townsend's transaction-focused practice is valued by a range of biotech and pharmaceutical companies. Litigator and regulatory lawyer Eleri Williams and product liability expert Ian Dodds-Smith are further names to note.
Responsables de la pratique:
Adela Williams
Autres avocats clés:
Ian Dodds-Smith; Jacqueline Mulryne; Beatriz San Martin; Ewan Townsend; Tom Fox; Libby Amos-Stone; Eleri Williams
Les références
‘The team’s offering is one of the best in the life sciences legal sector. I go to A&P for substantive expertise (both breadth and depth), industry knowledge, service-mindedness and value-for money.’
‘The individuals I work with at Arnold & Porter have a clear understanding of my company, our products and the broader industry environment. They consistently apply their legal expertise to that context, and provide tailored, legally and practically robust advice in line with my needs.’
‘The team I work with stand out due to their dedication to accuracy and their practical approach to legal matters.’
Principaux clients
Bayer
AstraZeneca
ABPI
Pfizer
Alexion
Janssen
Kyowa Kirin
Norgine
Orion Inc
Sanofi
Takeda
GSK
Principaux dossiers
- Acted for Bayer plc and Aventis Pharma (t/a Sanofi) in litigation arising from historic use of hormone pregnancy tests in the 1960s-1970s
- Acted for Orion Corporation in proceedings before the Court of Justice of the EU in defence of the regulatory data protection attached to one of Orion’s medicinal products.
- Represented Pfizer in negotiating multiple contracts with various governments and supranational bodies for supply and/or donation of the Pfizer/BioNTech COVID-19 vaccine and Pfizer’s antiviral medicinal product, Paxlovid
Baker McKenzie
‘The ‘skilled, multi-faceted and solution-orientated’ team at Baker McKenzie pulls together a strong offering combining transactional and regulatory expertise across the life sciences and healthcare sectors. Phelim O’Doherty heads up the team and is geared to handle work such as cross-border M&A, joint ventures and licensing arrangements. Jane Hobson’s transactional expertise is relied upon by the likes of Galapagos,among others. Joanna Ludlam has a proven track record in leading complex investigations and is praised for her ‘dedication to accuracy’. Industry code compliance and digital health applications are core areas of activity for Julia Gillert, while Alexander Gee is active across a range of transactional work and is noted for his ‘deep knowledge and experience’. Hiroshi Sheraton has left the firm.
Responsables de la pratique:
Phelim O’Doherty
Autres avocats clés:
Jane Hobson; Joanna Ludlam; Julia Gillert; Alex Gee; Patrick Edward; Daniel Relton; Indhu Birdy; Jaspreet Takha
Les références
‘We have worked with the team around Alexander Gee on a UK-DE M&A transaction, where we were on the buy side. The team was very skilled and hands-on and kept a constructive negotiation with the sellers even during very bumpy phases of the process.’
‘Alexander Gee stood out for his deep knowledge and experience and his very pragmatic way of balancing risk and legal costs in hedging such risks. Alexander was instrumental in also closely working with the German counterpart and was leading significant parts of the discussions.’
‘Skilled, multi-faceted and solution-orientated.’
Principaux clients
Ariceum Therapeutics
Bacthera
Baxter
Biogen
Donaldson
eMed
Galapagos NV
GED Capital
GSK
ICON plc
Johnson & Johnson
Lyra Health
Inceptua
Thriva Limited
Principaux dossiers
- Advised Galapagos NV on their sale of the Jyselca business, the trade name of the drug Filgotinib for the treatment of rheumatoid arthritis, for €170m to Alfasigma.
- Advised eMed on its successful acquisition of the UK assets of the distressed Babylon Health group from its administrators, Alvarez & Marsal.
Clifford Chance LLP
Data protection and cyber matters, financing for acquisitions and high-profile appeals of decisions made by the Competition and Markets Authority stand out as areas of activity for the team at Clifford Chance LLP. Stephen Reese and Gareth Camp jointly oversee the practice. Reese is equipped to advise clients on the UK and EU regulatory aspects of pharmaceuticals biologics and medical devices and their interplay with IP strategy, while Camp is frequently tasked with leading life sciences and healthcare transactions. Corporate compliance and investigations partner Luke Tolaini‘s practice extends to crisis management and ethical and compliance failings. Alex Walker focuses his practice on advising clients on the protection, exploitation, use and enforcement of their IP rights.
Responsables de la pratique:
Stephen Reese; Gareth Camp
Autres avocats clés:
Luke Tolaini; Alex Walker
Principaux clients
Pfizer
Cinven
EQT Infrastructure
GE HealthCare
Xellia Pharmaceuticals ApS and
Alpharma LLC (“Alpharma”)
Gilead Sciences
Her Majesty’s Government (HMG), Department for Business, Energy and Industrial Strategy (BEIS)
Principaux dossiers
- Acting for Cinven in relation to a high-profile appeal before the Competition Appeal Tribunal (“CAT”) against CMA Decisions for the alleged antitrust infringements of a former portfolio company active in generic pharmaceuticals, now named Advanz.
- Advised a Medicinal Cannabis developer and manufacturer in connection with an IP licensing contractual dispute concerning their global development and commercialisation of Cannabis medicinal products.
- Assisting a global pharmaceutical and healthcare corporation with various data protection and cyber matters.
CMS
CMS is praised for its ‘international capabilities and ‘broad range of expertise’ which encompasses commercial, regulatory, patent litigation and corporate work. Patent expert Robert Stephen leads the practice alongside Sarah Hanson and investment and development transactions specialist Candice Blackwood. Hanson excels in commercial, IP and outsourcing transactions. Shuna Mason is frequently sought out by medical device manufacturers for assistance with product liability mandates, while Brian Sher is a key contact for competition matters in the healthcare space. Glasgow-based Carina Healy ‘s commercial and IP expertise has made her a key contact for academic and research institutions on their research, licensing and commercial needs, and Healy’s Glasgow colleague David Dennis excels in clinical trial and collaboration agreements. Fionnuala Rice further augments the group’s patent litigation strength.
Responsables de la pratique:
Robert Stephen; Sarah Hanson; Candice Blackwood
Autres avocats clés:
Shuna Mason; Brian Sher; Carina Healy; Theo Godfrey; Hannah Curtis; Jane Evenson; Caitlin Heard; David Dennis; Jennifer Bass; Fionnuala Rice; Elizabeth-Anne Larsen; Sarah Klaczynska; Lauren Gregory; Frances Lowe
Les références
‘CMS has international capabilities and a broad range of expertise which can be drawn on when required without the costs of some of the global firms’.
‘Carina Healy is our relationship partner. She provides high levels of service as well as having excellent in depth knowledge of pharma industry issues. She also provides pragmatic cost effective advice on her main area of engagement, commercial contracts.’
‘CMS is one of the strongest city firms in this sector. They have real and deep rooted expertise in regulatory Issues and in litigation involving medical devices. They deliver a Rolls-Royce service to some of the world’s most successful life sciences companies. Shuna Mason is superb.’
Principaux clients
Akebia Therapeutics
Alliance Pharma
Amber Therapeutics
Astellas Pharma
Awakn Life Sciences ( Via / Amitis Partners)
Beckley Psytech
E-Therapeutics
ESMS Global
GlaxoSmithKline
Johnson & Johnson
Marie Curie
Orb Innovations
Sanofi
Sareum Holdings
Skin Analytics
The Wellcome Trust
Thermo Fisher Scientific
University College London
Varian Medical Systems
Zoe Global
Principaux dossiers
- Advised Alliance Pharma PLC, a leading international healthcare business, on its appeal to the CAT, heard over a split 5 week trial in June to August 2023, following the CMA’s enforcement decision in its investigation into the supply of Prochlorperazine, a medication used for treating nausea.
- Advised Beckley Psytech on its Series C fundraising round led by Atai Life Sciences. This investment and collaboration aims to accelerate the development of Beckley Psytech’s two clinical-stage, patent-protected, short-duration psychedelic candidates, BPL-003 and ELE-101, by adding them to Atai’s mental health innovation platform.
- Advising Akebia Therapeutics in an ongoing patent dispute with Fibrogen concerning their product Vadadustat® and the alleged infringement of Fibrogen patent claims for a broad class of compounds, defined by structure and function, to be used for treating specified types of anaemia.
Cooley (UK) LLP
The team at Cooley (UK) LLP is jointly overseen by John Wilkinson, known for his prowess in handling large-scale alliances and joint ventures, and Nicola Maguire, who handles a range of IP and transactional issues such as high-profile collaborations and strategic investments. Transactional work is a mainstay of the practice with series investments and debt and equity financings notable areas of activity. Colm Murphy is geared to assist life sciences clients with their IP strategy, while Frances Stocks Allen excels in handling the IP aspects of major life sciences deals. Joe Sandys further extends the unit’s transactional expertise and frequently advises on licensing and M&A matters.
Responsables de la pratique:
Nicola Maguire; John Wilkinson
Autres avocats clés:
Colm Murphy; Frances Stocks Allen; Joe Sandys; Simon Amies; Michael Fernando
Les références
‘I have worked with several different law firms over the years and what makes Cooley stand out is the way that pragmatism and flexibility is combined with a high degree of expertise that allows rapid project engagement and understanding of what we need as a client, as well as the ability to focus on the key issues. ’
‘The Cooley team is very friendly, informal and easy to collaborate with. There is high attention to detail and high quality in the work.’
‘We are particularly impressed with the work of Joe Sandys. He combines those qualities displayed by the team in general with the ability to quickly analyse, draw on his deep knowledge, direct us appropriately and deliver quality.’
Principaux clients
Allergy Therapeutics plc
Athenex
Amryt Pharma
Ascend
AstronauTx
Bavarian Nordic
Bicycle Therapeutics
Broken String Biosciences
CEPI
Coalition for Epidemic Preparedness Innovations’ (CEPI)
DJS Antibodies
Emergex
EyeBio
Hummingbird Bio
Illumina
Medicxi III LP
Oyster Point Pharma
Quell Therapeutics
VectivBio
Zealand Pharma
Principaux dossiers
- Advised Quell Therapeutics, a leading T-regulatory (Treg) cell therapy biotech company based in London, on its exclusive collaboration with AstraZeneca.
- Advised Bicycle on a noteworthy follow-on offering. After closing lucrative collaboration deals with Novartis and Bayer, Bicycle executed a US$230 million follow on of ADS and non-voting ordinary shares.
- Advised AstronauTx, a biotech company aiming to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders, on its US$117 million collaboration agreement with Saniona in Alzheimer’s disease.
Gowling WLG
The likes of GlaxoSmithKline, Lundbeck and Neurim Pharmaceuticals turn to the team at Gowling WLG for assistance with issues spanning patent disputes, IP portfolio management, joint ventures, M&A, and commercial agreements. The unit is also active across digital health and well-placed to assist funders and operators of care homes and senior living facilities with a range of issues. Jenny Davies co-heads the practice alongside Robert Breedon, who divides his time between Birmingham and London. Davies’ practice spans patent litigation and strategic collaborations, while Breedon frequently leads on large healthcare projects. Paul Inman has a proven track record in multi-jurisdictional patent litigation. Patrick Duxbury‘s varied caseload includes global collaborations and co-commercialisation deals. Huw Evans‘ busy portfolio of work includes patent entitlement cases in the French and Spanish Courts. Luke Kempton’s scientific expertise is particularly prized by Japanese companies seeking assistance with drug acquisition, collaboration and licensing deals. Mathilda Davidson specialises in transactional IP matters, while patent expert Christopher Freeth has notable experience with Arrow declarations.
Responsables de la pratique:
Jenny Davies; Robert Breedon
Autres avocats clés:
Patrick Duxbury; Paul Inman; Huw Evans; Ian Piggin; Luke Kempton; Neil Hendron; Sharmela Kalmer; Hugh Maule; Samantha Myers; Mathilda Davidson; Christopher Freeth
Principaux clients
BioNTech
Gyrus Capital
Neurim Pharmaceuticals
European Pharmaceutical Company
AstraZeneca
Eisai
Bial Portela
Katholieke Universiteit Leuven
GlaxoSmithKline
Apposite Capital
Sosei Heptares
Achilles Therapeutics
Levicept
Fresenius Medical Care Renal Services Limited
Getinge Group (includes ArjoHuntleigh UK, Arjo Ltd Med AB, Arjo Med Aktiebolag, Altrax Group, Getinge Infection Control AB, Getinge UK)
Guy’s & St Thomas’ NHS Foundation Trust
Montreux Healthcare Fixed Yield Fund (inc. Huntercombe Group)
NHS Birmingham and Solihull Mental Health NHS Foundation Trust
Oxford BioTherapeutics
Immedica Pharma AB
Lundbeck
Arjo
LRE Medical
Corcym
Millbrook
Emed
Chroma Therapeutics
Principaux dossiers
- Advised long-standing client AstraZeneca on a collaboration and license agreement with biopharmaceutical company Quell Therapeutics, in relation to the development and manufacturing of cell therapies.
- Advised BioNTech on their collaboration with the UK Government to accelerate personalised mRNA immunotherapy clinic trails providing personalised cancer therapies for up to 10,000 patients by 2030.
- Acting for Neurim Pharmaceuticals in a series of fast-paced and unusual disputes with Viatris, involving a series of procedurally complicated events in the dispute over a patent for Circadin.
Herbert Smith Freehills LLP
Praised for its ability to see ‘the forest and the trees’, Herbert Smith Freehills LLP pulls together a strong offering that includes seed financing, patent protection, commercial disputes, M&A, merger control and regulatory matters. Alan Montgomery co-leads the practice and is geared to handle a range of cross-border transactional work in the life sciences sector. Fellow co-leadChris Parker KC‘s contentious expertise is frequently relied upon by major pharmaceutical clients. The ‘client-friendly’ Sebastian Moore is a known name for co-ordinating patent litigation cases across Europe. Brussels-based Kyriakos Fountoukakos frequently advises life science sector clients on M&A transactions. Andrew Wells is well-placed to handle IP enforcement strategy. R&D-based pharmaceutical companies trust Jonathan Turnbull with a range of commercial mandates.
Responsables de la pratique:
Alan Montgomery; Chris Parker KC
Autres avocats clés:
Sebastian Moore; Kyriakos Fountoukakos; Hannah Ambrose; Andrew Wells; Jonathan Turnbull; Emily Bottle; Priyanka Madan
Les références
‘Smart, careful, ability to see the forest and the trees. Great ability to learn complex issues. Delivers advice that makes sense for the business, not just at law.’
‘Partner Sebastian Moore is very client-friendly, responsive and easy to work with.’
Principaux clients
Gilead Sciences, Inc
AbbVie, Inc
Roche
Genus plc
Abcam plc
Biotage AB
Johnson Matthey plc
CSL Behring
Sanofi
Biogen
Principaux dossiers
- Advising Sanofi in a number of key jurisdictions – including the UK, France, Germany, and Italy, in developing litigation strategy for its multiple sclerosis drug, Aubagio®.
- Advised Biotage AB on its acquisition of Astrea Bioseparations, a high-growth chromatography solutions provider from Gamma Biosciences.
- Advising RTW Biotech, an investment fund focused on transformative biotech and medtech companies, on its recommended all-share acquisition of Arix’s assets by RTW Biotech.
Linklaters LLP
Praised for its ability to provide creative solutions tailored to bespoke situations, Linklaters LLP assists a litany of major pharmaceutical, biotech, digital health and medical device companies with work including transactions, patent and trade mark litigations and licensing disputes. Marly Didizian, described as ‘first choice for the tricky stuff’, co-heads the team and is noted on the market for her ability to handle high-profile pharma mergers and carve-outs. Fellow co-head Aisling Zarraga is equipped to handle matters spanning M&A, joint ventures and corporate governance advisory work. IP expert Yohan Liyanage assists clients with IP transactions and patent litigation. Trade mark and patent disputes are staples of Ian Karet‘s far-reaching practice. Katie Coltart has a proven track record in coordinating cross-border patent litigation.
Responsables de la pratique:
Aisling Zarraga; Marly Didizian; Yohan Liyanage
Autres avocats clés:
Ian Karet; Katie Coltart; Marc Harvey
Les références
‘The team is able to navigate complex environments and provide creative solutions tailored to bespoke situations. A key strength is their client knowledge and availability of key partners that helped us to manage material risks.’
‘I have valued the team’s ability to operate as a sounding board. Partners were always available to help. Marly Didizian and Aisling Zarraga were instrumental in structuring and providing advice. Particular praise in the last year should go to Marc Harvey for his work in navigating complex cross-border disputes.’
‘Excellent knowledge and collegiate team. ’
Principaux clients
Gavi, the Global Vaccines Alliance
Apax Partners
The Carlyle Group
Fresenius
PAI Partners
Hg Capital
Bayer
Nestlé
Takeda Pharmaceuticals
McKesson Corporation
Merck & Co., Inc.
Sanofi
Regeneron Pharmaceuticals
ViiV
Thermo Fisher Scientific Inc
Principaux dossiers
- Advised Thermo Fisher on its £2.3bn acquisition of The Binding Site Group.
- Advising Novo Holdings A/S on the merger control, foreign investment and foreign subsidies aspects of its proposed $16.5bn acquisition of Catalent.
- Advised Tesaro, a subsidiary of GSK plc, in defending a lawsuit filed by AstraZeneca worth several hundred million pounds. In February 2024, the Court of Appeal handed down its judgment unanimously finding for Tesaro and allowing the appeal, representing a significant win for our client.
Osborne Clarke LLP
A range of multinational biopharmaceutical and medical device companies turn to Osborne Clarke LLP for assistance with work such as multi-jurisdictional patent litigation, life sciences M&A and financing transactions. A foursome of partners oversee the team: Will James‘ contentious IP expertise has seen him litigate before the UK courts and the UPC. Matthew Edwards is praised for his ‘smooth and successful’ handling of transactions. His corporate expertise is relied upon by the likes of BioNtech. Marcus Vass is well-versed in the digital health sector, and Richard Wilkinson heads up the firm’s healthcare subsector. Tim Harris is a further key contact and extends the unit’s international IP litigation strength.
Responsables de la pratique:
Will James; Matthew Edwards; Marcus Vass; Richard Wilkinson
Autres avocats clés:
Trevor Crosse; Laurence Nelson; Tim Harris
Les références
‘We use Osborne Clarke LLP principally for mid-market M&A support. It’s their sweet spot and the team delivers. Clear communication, understanding of our business and what is important to us (acceptable vs unacceptable risks), responsive, deliver under pressure, collaborative and most importantly nice to work with. ’
‘Matthew Edwards is a delight to work with, understands our business and helps deliver transactions in a smooth and successful manner.’
‘Laurence Nelson is a rising star of the OC corporate team. ’
‘Will James, Trevor Crosse and their life science IP team are a strong team with broad expertise. They rate very highly for their innovative and excellent solutions and ability to win cases and maximize opportunities. ’
‘Will James is a first-rate litigator, able to see the big picture and bring innovative solutions to the matters he manages. He can get the best out of people and teams, and his personable manner makes him a pleasure to work with.’
‘Trevor Crosse has a real depth of knowledge across IP and regulatory life sciences. He is responsive, detail-oriented and thorough. I trust Trevor to get into the weeds on any issue and root out the key issues then provide pragmatic and actionable advice.’
Principaux clients
Santen
BioNTech
Amgen
Basecamp Research
King’s College London
AviadoBio
NeRRe Therapeutics
Koa Health
Uniphar
Albion Capital/UCL Technology Fund
Principaux dossiers
- Advised multinational biotechnology company BioNtech SE on its acquisition of AI start-up Insta Deep in a US$562 million deal.
- Advising Santen in relation to its leading ophthalmic products for the treatment of glaucoma and high intra-ocular pressure.
- Advised OMERS on the acquisition of a portion of Enanta Pharmaceuticals’ royalty entitlement relating to the antiviral medication Maviret (glecaprevir).
Sidley Austin LLP
Known for its ability to handle regulatory issues relating to orphan drugs, cell and gene therapy products, and digital health tools, Sidley Austin LLP is additionally active across areas including product liability, cybersecurity, M&A, and collaborations and licencing. Maria Isabel Manley leads the life sciences team for Sidley's office in London and frequently brings her knowledge of EU and UK regulatory and competition law to bear when representing clients before regulatory authorities. Robert Darwin is a key contact for global life sciences and healthcare corporations looking to do transactions. James Wood is well-placed to handle M&A work in the sector. Solicitor advocate Chris Boyle, and Zina Chatzidimitriadou, who excels in market access strategy matters, are further recommended.
Responsables de la pratique:
Maria Isabel Manley
Autres avocats clés:
Robert Darwin; James Wood; Chris Boyle; Zina Chatzidimitriadou
Les références
‘Chris Boyle is a vet as well as lawyer, so he understands the animal health industry first hand and speaks our language! Chris has instigated an Animal Health Legal Forum, bringing together others in he industry, which is a great innovation.’
‘Marie Manley and Chris Boyle are both stand out lawyers. They are approachable, straight-talking and pragmatic. They are clearly both experts in their areas, and we trust and value their advice. ’
‘The team represeents the wide range of practices required to thrive in the Pharma industry.’
Principaux clients
Les Laboratoires Servier
Arat Health, Inc.
Perspectum Group Ltd.
Savillex Corporation
Carlin Consumer Health
Redmile Group LLC
Immunocore
Principaux dossiers
- Supported and represented Immunocore in its successful appeal against a NICE decision to refuse to recommend a life-extending cancer therapy available to patients with rare eye cancer.
- Representing French pharmaceutical company Les Laboratoires Servier as co-lead counsel before the Court of Justice of the European Union (CJEU) in appeals by Servier (Case C-201/19 P) and the European Commission (Case C-176/19 P) against a General Court judgment (Case T-691/14).
- Advising Arat Health, Inc. on establishing the Roha Medical Campus, a groundbreaking hospital and medical complex in Addis Ababa, Ethiopia.
Simmons & Simmons
Key pillars for the ‘excellent’ team at Simmons & Simmons are transactional work, regulatory issues, patent litigation and product liability. The unit is additionally increasingly active in the digital health space with practice head Michael Gavey a key driver behind the firm’s strength in this area. Lydia Torne is well versed in the intricacies of life sciences IP transactions, and Michael Burdon is highly experienced in the field of patent litigation. Scott Parker is hailed as ‘one of the more impressive UK litigators in life sciences’, while Emily Agnoli specialises in investigations for corporate crime and has a particular focus on the life sciences sector.
Responsables de la pratique:
Michael Gavey
Autres avocats clés:
Lydia Torne; Michael Burdon; Scott Parker; Emily Agnoli; Andrew Hutchinson; Amy Crouch
Les références
‘Simmons & Simmons London life sciences practice perhaps flies a bit under the radar, but it really shouldn’t because it’s excellent. Although I’ve only worked with a subset of the people there, they are a strong team who do great work in co-ordinating litigation across jurisdictions, and in representing their clients in the UK courts.’
‘Scott Parker is a very thoughtful and effective partner. He has a strong analytical mind and a good instinct, which make him one of the more impressive UK litigators in life sciences.’
‘Christina Thompson is an extremely able associate who knows her way around the life sciences sector, and is a pleasure to work with.’
Principaux clients
GSK, Amgen, AstraZeneca, Merck Sharp & Dohme, Johnson & Johnson, Alnylam, Roche and Regeneron.
Samsung Bioepis
Cooper Consumer Health
Boston Scientific Corporation
Ascendis Pharma
Whoop
uniQure and CSL Behring
Novartis
Odin Medical Limited
Altea Insurance
Samsung Bioepis
Principaux dossiers
- Advising Samsung Bioepis on a number of ongoing matters, including patent litigation for SB17, a biosimilar to reference medicine Stelara® (usetkinumab) and SB12, a biosimilar to reference medicine Soliris (eculizumab).
- Advising Cooper Consumer Health on its acquisition of Viatris’ worldwide OTC business, which includes well-known brands, two production sites and a research and development site.
- Facilitated a strategic partnership for Ascendis Pharma, granting Teijin Limited an exclusive license in Japan for Ascendis’ innovative pro-drug technologies named TransCon hGH, TransCon PTH, and TransCon CNP – for endocrinology rare diseases in Japan.
Taylor Wessing LLP
The ‘helpful, knowledgeable, and collaborative’ team at Taylor Wessing LLP showcases a diverse range of expertise, particularly in venture capital transactions within the biotech sector, patent litigation and advisory work for growth companies. Alison Dennis co-leads the practice and frequently leverages her broad knowledge in IP, compliance and contractual issues to advise pharmaceutical clients and medical device manufacturers. Fellow co-head Andrew Edge has extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings. Nigel Stoate excels in patent litigation and frequently co-ordinates multi-jurisdictional cases. In Cambridge, Ross McNaughton focuses on the biotech domain, primarily supporting clients with corporate advice and capital raising. His Cambridge colleague Adrian Toutoungi, with his particular experience in biologics and small-molecule therapeutics, advises on life science licensing mandates. Colin McCall also assists clients with licensing agreements and R&D projects, while Charlie Adams frequently brings his IP knowledge to bear on work with life sciences incubators and accelerators.
Responsables de la pratique:
Alison Dennis; Andrew Edge
Autres avocats clés:
Nigel Stoate; Simon Cohen; Matthew Royle; Tasmina Goraya; Colin McCall; Ross McNaughton ; Adrian Toutoungi; Amanda Ebbutt; Katie Chandler; Andrew Edge; Suzy Davis; Victoria Hordern; Charlie Adams
Les références
‘It has been an absolute pleasure working with Taylor Wessing. The team has been really helpful, knowledgeable, and collaborative.’
‘Colin McCall is a really knowledgeable person, always happy to help. He is also a genuinely nice person and very easy to work with.’
‘Ross McNaughton has been very helpful in ensuring that we are fully aware of all aspects of a transaction before making a decision. He’s very knowledgeable and very good at providing reassurance.’
Principaux clients
Pfizer Inc
Glenmark Pharmaceuticals Europe Limited
Viatris
Essential Pharma
Apollo Therapeutics
Shield Therapeutics Plc
LivaNova Deutschland GmbH
Creative Lynx Limited
AlveoGene
Theramex
Infinitopes
Tagomics
DAC Beachcroft LLP
DAC Beachcroft LLP’s diverse team is renowned for its expertise in product liability cases and deep knowledge of both the NHS and private healthcare sectors. The unit is additionally well-placed to advise on the regulation of pharma and medical devices. The practice is led by the ‘fantastically good‘ Alison McAdams who has extensive experience advising on clinical trial claims. Medtech expert Hamza Drabu excels in commercial transactions in the NHS. Darryn Hale has a proven track record in matters that fall at the nexus between public and data protection law. Olya Melnitchouk is notably active across ophthalmic product liability claims.
Responsables de la pratique:
Alison McAdams
Autres avocats clés:
Hamza Drabu; Darryn Hale; Olya Melnitchouk; Andrew Johnston; Emily Broad
Les références
‘Absolutely the best – a blend of scientific understanding, legal understanding and experience, combined with practical good sense.’
‘Alison McAdams is fantastically good, able to get to grips with the most complex scientific evidence, but to do so with practicality and good sense combined with toughness.’
‘The team have a wealth of knowledge regarding the regulatory minefield that governs the life sciences industry and is able to apply that knowledge to our specific and often unique circumstances. ’
Principaux clients
NHS England
NuVasive
Ipsen Pharma
Circle
Deltex Medical
Simply Health
Optegra UK Ltd
Oxford University Hospitals NHS Foundation Trust
Teladoc Health
Fertility Mapper
Institut Mérieux via Freshfields
Globus Medical
Principaux dossiers
- Acting for NHS England in connection with all modules of the Covid-19 Public Inquiry.
- Instructed to advise the Oxford University Hospitals NHS Foundation Trust/NHS Resolution in relation to its contribution to the Infected Blood Inquiry. The Trust is a key contributor to the public statutory inquiry.
- Providing NuVasive with extensive commercial support across its operations, including with its distribution and agency agreements and framework agreements for direct sales.
Fieldfisher
Fieldfisher‘s team, renowned for its ‘deep understanding of the life science landscape in the UK‘ handles work spanning key stage funding for novel transactional funding for pharmaceutical products, regulatory assistance in areas of new technologies and M&A work in the life sciences space. ‘Very experienced operator’ Janita Good heads up the team and is equipped to assist clients with M&A exits and pharma IP partnering deals. Sarah Ellson is frequently called upon to assist with appeals against commercial decisions made by NICE. Vicky Reinhardt, dual qualified in Germany and England, is well placed to assist life sciences clients with the commercial exploitation of products.
Responsables de la pratique:
Janita Good
Autres avocats clés:
Sarah Ellson; Vicky Reinhardt; Joshua Cronin
Les références
‘The team has domain expertise, market knowledge and understanding, a network in the sector and a track record and experience.’
‘Janita Good is a very experienced operator in the Life Science sector in the UK and she is very skilful at finding clever solutions to thorny issues and getting projects successfully over the line.’
Principaux clients
ALSA Ventures
Link Biologics
Novartis
Inspiration Healthcare plc
Syneos Health UK
LetterOne
Human Tissue Authority
NHS Resolution
Phoenix Healthcare/Numark
General Medical Council
Sinclair Pharma
UK BioBank
Complement Therapeutics
Jersey Hemp
Randox Laboratories
Principaux dossiers
- Advised Link Biologics on a simultaneous in-licence from the University of Manchester and out-licence to French pharmaceutical company Laboratoire Thea and its affiliate Thea Open Innovation.
- Advised blood cancer charity Myeloma UK on two separate successful appeals against decisions made by the National Institute for Health and Care Excellence (NICE).
- Advised Novartis on local regulations and legislation in relation to Patient Support Programmes (PSPs) in over 38 countries.
Goodwin
Biotechnology, pharmaceutical and healthcare companies as well as leading venture capital and investment firms turn to Goodwin for assistance with work spanning early stage financings, capital markets, M&A, dispute resolution and licensing transactions. Four partners lead the team: David Mardle, who divides his time between Cambridge and London, has a focus on assisting emerging companies with corporate and capital markets transactions. Graham Defries is a key contact for private equity and venture capital investments and exits. Sophie McGrath‘s corporate practice encompasses private and public financings, public offerings, and restructurings. Arvin Abraham, completing the leadership team, is frequently sought out by private equity sponsors for transactional assistance. Malcolm Bates‘ wide-ranging practice spans outsourcing and R&D projects, M&A transactions and IPOs.
Responsables de la pratique:
David Mardle; Graham Defries; Sophie McGrath; Arvin Abraham
Autres avocats clés:
Malcolm Bates; Tim Worden; Andrew Harrow; Morag Peberdy; Elizabeth Rhodes; Kenny Walker-Durrant; Maria Dragun
Les références
‘Specifically to investments and medtech – as the depth of the roster crosses all side of transactions, they are confident in their advice and are sure that one of their team will have been through the specific situation being faced. Everyone on the team is an A* player.’
‘Sophie McGrath stands out as she is calming and well-experienced. Her skill is in assembling a group of the right people for each case and remaining in the detail to be sure there is nothing missed.’
‘Professional, great attention to detail, commerical acumen and busines practiciality. Take time to get a deep understanding of our business and requirements over the next few years.’
Principaux clients
Emergence Therapeutics AG
COMPASS Pathways plc (Nasdaq: CMPS)
Calypso Biotech B.V.
Gimv, Cambridge Innovation Capital, Panakes Partners, Seroba Life Sciences, Hadean Ventures
Closed Loop Medicine
Synaffix
Jeito
Sofinnova
Novo Holdings
Fulcrum Therapeutics, Inc. (“Fulcrum”)
Adrestia Therapeutics Ltd
MiNA Therapeutics
Tay Therapeutics
Dawn Biopharma, a platform controlled by KKR
30 Technology
Astex Therapeutics Limited
CMR Surgical
Novartis Bioventures Limited
Okra Holdings Limited
Principaux dossiers
- Advised COMPASS on the completion of the closing of a private investment in public equity (PIPE) financing.
- Advised Calypso Biotech B.V. and its selling shareholders on its sale to Novartis Pharma AG for US$250 million upfront payment with the potential for shareholders to receive additional contingent payments of up to US$175 million based on the achievement of certain predetermined milestones.
- Advised Gimv, Cambridge Innovation Capital, Panakes Partners, Seroba Life Sciences and Hadean Ventures on their investment into Complement Therapeutics (“CTx”) as part of its EUR 72 million Series A financing. Existing investors Forbion and BioGeneration Ventures also participated in the round.
Kirkland & Ellis International LLP
Described as ‘one of the best teams in life sciences and healthcare in London’ Kirkland & Ellis International LLP advises a multitude of major life sciences companies on the global formulation and coordination of life science patent litigation strategy. Daniel Lim co-heads the practice and has a proven track record in pharmaceutical and medical device litigation. Fellow co-head Nicola Dagg is a known name for work including strategic patent and product lifecycle advice. Emma Flett completes the leadership team and is geared to advise on the of IP aspects of M&A transactions. SPC disputes relating to biologic and small molecule products are a practice strength of Steven Baldwin, while Jin Ooi works extensively on follow-on damages inquiry mandates.
Responsables de la pratique:
Daniel Lim; Nicola Dagg; Emma Flett
Autres avocats clés:
Steven Baldwin; Jin Ooi
Les références
‘The team is one of the best teams in life sciences and healthcare in London today.’
‘The team is extremely impressive, with real strength and depth. Members of the team work seamlessly together to achieve the best outcome for the client. The team’s technical, legal and commercial knowledge is exceptional. ’
‘Nicola Dagg – a star. Highly intelligent, she understands her client’s needs and objectives and is able to utilise her legal talent to obtain fantastic results.’
Principaux clients
Warner-Lambert Company LLC (part of the Pfizer group)
Viatris
British American Tobacco (reduced risk products)
Pfizer
Alcon
Advanced Bionics
Pharmathen
Siemens Healthineers
Meril Life Sciences
Principaux dossiers
- Instructed by Astellas and he Regents of the University of California on an end of patent life/lifecycle management mandate in relation to Astellas’ prostate cancer treatment Xtandi.
- Successfully represented Pfizer in relation to its patent revocation action against Amgen to ‘clear the way’ for a BCMA/CD3 bispecific antibody for the treatment of cancer (in particular multiple myeloma) being developed by Pfizer.
Latham & Watkins
Hailed as a ‘great firm to go to for big matters’, Latham & Watkins assembles a robust offering with M&A, carve-outs, and shareholder activism claims among the unit’s diverse workload. Robbie McLaren oversees matters and counts life sciences venture and growth capital investments among his practice strengths. Emily Cridland‘s experience includes acting for clients on both the buy- and sell-side of share sales. Jenna Gascoyne‘ is a popular choice for clients seeking assistance with capital markets transactions such as private placements. Samantha Peacock‘s far-reaching corporate practice extends to advising on investments and reorganisations.
Responsables de la pratique:
Robbie McLaren
Autres avocats clés:
Emily Cridland; Jenna Gascoyne; Samantha Peacock; Oliver Mobasser; Antonina Semyachkova; Shing Lo; Gail Crawford
Les références
‘The Latham team is incredibly responsive and dependable. I’ve had great interactions with the team. Latham is known for its broad and diverse practice, and I know that any legal question, on any topic, can be addressed.’
‘The Latham team stands out by their promptness and dedication. We’ve built a good relationship and they know what our goals are. Samantha Peacock has been a great partner for us.’
‘Diverse, talented team with relevant expertise.’
Principaux dossiers
- Advised Abcam, a producer, distributor and seller of protein research tools, on a definitive agreement pursuant to which Danaher Corporation will acquire all of the outstanding shares of Abcam for US$24 per share in cash, with a total enterprise value of approximately US$5.7 billion including assumed indebtedness and net of acquired cash.
- Advised Patient Square Capital and Apollo Therapeutics on the Patient Square lead US$226.5 million Series C financing round of Apollo Therapeutics. This was the largest bio-tech financing in the UK in 2023.
- Advised BenevolentAI on its business combination with Odyssey Acquisition S.A.. The high-profile transaction values BenevolentAI at €1.5 billion and represents the largest-ever listing of a biotech company on Euronext Amsterdam and one of the largest-ever European listed deSPACs.
McDermott Will & Emery UK LLP
Lauded for advice that ‘balances the risks and benefits of any given approach clearly’, McDermott Will & Emery UK LLP is active across regulatory matters such as medical device certifications and transactional work spanning M&A, IP transfers and growth capital investments. Sharon Lamb heads up the team and has a far-reaching practice spanning commercial, regulatory and transactional expertise. Hamid Yunis is a key contact for private equity transactions. Michal Berkner, who joined from Cooley (UK) LLP in February 2024, further bolsters the team’s transactional capacities and counts takeover defences, corporate governance, and joint ventures among her practice strengths. David Gibson and Bella North are further key names to note.
Responsables de la pratique:
Sharon Lamb
Autres avocats clés:
Hamid Yunis; Michal Berkner; Eleanor West; Gary Howes; Gary Howes; Bella North
Les références
‘Their understanding of the environment in which their clients are working is exceptional, and their advice balances the risks and benefits of any given approach clearly. They are responsive and flexible. ’
‘Sharon Lamb is the best partner I have ever worked with and her support of navigating some very challenging situations has been above and beyond expectations. Her contribution to our organisation is more than just her legal excellence as she also supports another important aspect of our work in the healthtech sector such as diversity and inclusion.’
‘Good broad knowledge of the life sciences area – with the ability to span US and Europe.’
Principaux clients
Novartis Groupe France SAS
Zura Bio Limited
Vesey Street Capital Partners
Fortius/Affidea
ProductLife Group Limited
I.Q. Endoscope
Supporting Wounded Veterans Limited
Ampersand Capital Partners
Principaux dossiers
- Advised Novartis Groupe France SAS on the sale of the company CellforCure and its cell and gene therapy development and production site in Les Ulis, France, to Seqens SAS.
- Advised Vesey Street Capital Partners (“VSCP”), a New-York based sector specialist PE firm investing in pharma services companies on the acquisition of the Inceptua group of companies (“Inceptua”) (“Inceptua Acquisition”) and the investment, by the primary seller and Inceptua management in the equity structure going forward (“Inceptua Investment”).
- Advised Zura Bio Limited on several transactions including, on its licence and collaboration agreement with Eli Lilly & Company, whereby Zura acquired rights to potential autoimmune disease drug tibulizumab (renamed ZB-106) from Lilly.
Powell Gilbert LLP
Powell Gilbert LLP has developed a market reputation for high-profile IP litigation and advisory work and is praised for its ‘unparalleled collective knowledge in the life sciences patent litigation field’. Penny Gilbert leads the team and has amassed considerable experience in UK and European patent litigation. Zoë Butler’s board practice extends to patent entitlement disputes. Bethan Hopewell frequently represents clients in technically complex proceedings concerning issues such as therapeutic nucleoside analogues. Tim Whitfield, who divides his practice between London and Dublin, is frequently called upon to co-ordinate multi-jurisdictional patent litigation campaigns.
Responsables de la pratique:
Penny Gilbert
Autres avocats clés:
Zoë Butler; Bethan Hopewell; Tim Whitfield; Peter Damerell; Tom Oliver; Siddharth Kusumakar; Joel Coles; Tess Waldron; Bryce Matthewson
Les références
‘Firm has an unparalleled collective knowledge in the life sciences patent litigation field.’
‘They combine knowledge with superlative communication skills, excellent experience in their field and an appreciation of the commercial realities.’
Principaux clients
Biogen v AbbVie / Biogen v Fresenius / Biogen v Gedeon Richter
Biogen v Sandoz, Polpharma
Edwards Lifesciences
BioNTech
DSM IP ASSETS B.V. & DSM NUTRITIONAL PRODUCTS AG
Oxford University Innovation and the University of Oxford
Otsuka Pharmaceuticals Co Ltd
Cook Medical
NuCana plc
MED-EL
Glenmark
UCB Biopharma SRL, LTS Lohmann Therapie-Systeme AG
Nador Cott Protection S.A.S.
Principaux dossiers
- Representing Biogen in litigation over its biosimilar of AbbVie’s blockbuster drug Humira™ – the biggest selling prescription drug worldwide.
- Representing BioNTech in UK infringement and revocation proceedings concerning multiple EP (UK) patents held by Moderna and CureVac and in proceedings relating to Moderna’s “patent pledge” made at the start of the COVID-19 pandemic when it stated that it would not enforce its IP rights.
Ropes & Gray
Lincoln Tsang heads up a team at Ropes & Gray LLP whose offering spans transactional, regulatory, litigation and enforcement matters and is praised for its ‘unsurpassed knowledge of the laws and regulations covering the pharma and biotech industries.’ Tsang frequently brings his regulatory expertise to bear on internal investigations and public policy matters concerning the life sciences industry. David Dowling is active across venture capital investments and private M&A. Hannah Kerr-Peterson further extends the regulatory expertise at the firm.
Responsables de la pratique:
Lincoln Tsang
Autres avocats clés:
David Dowling; Hannah Kerr-Peterson; Daisy Bray
Les références
‘The practice excels in crafting regulatory strategies central to the preservation of exclusivity of important pharmaceutical products for key pharma clients while avoiding risks of claims by competitors of anti-competitive behavior, managing potential enforcement actions as well as product liability claims that may arise from drug safety and defending companies in promotional disputes with key competitors.’
‘Lincoln Tsang enjoys unparalleled standing and credibility in the life sciences sector based on his extensive experience both as a regulator and long-standing outside counsel to numerous bio-pharmaceutical and med tech companies. He is extremely knowledgeable and practical with the ability to handle technically complex and legally challenging mandates. His practice is supported by a team of up-and coming- next generation practitioners, notably Hannah Kerr Peterson and Daisy Bray.’
‘The team at Ropes and Gray have an unsurpassed knowledge of the laws and regulations covering the pharma and biotech industries and, more unusually, this knowledge is combined with an excellent feel for the complexities and nuances of actually running such a company. Their advice stands apart for its practicality and usability. They also combine this with being genuinely nice and easy to work with.’
Principaux clients
Bain Capital
NeoGenomics
Avista Capital Partners
Blackstone Group
Novavax
Pfizer
PTC Therapeutics
Takeda Pharmaceuticals International
Merck KGaA
Sarepta Therapeutics, Inc.
Chroma Medicine, Inc.
ConforMIS, Inc.
Bluebird
Orphalan (previously Gmp-Orphan)
Horizon Therapeutics
BioMarin
Intrabio
Nasus Pharma
Mirum Pharmaceuticals
Akebia Therapeutics, Inc.
Spruce Biosciences
Gyroscope Biotherapeutics
Ipsen Biopharmaceuticals
Kyowa Kirin Co.
Amicus Therapeutics
Allergan
Actimed Therapeutics
Principaux dossiers
- Advised Advent International and Warburg Pincus on their investment in Baxter International Inc.’s BioPharma Solutions (BPS) business. Under the terms of the definitive agreement, Baxter will receive $4.25 billion in cash, subject to certain closing adjustments.
- Successfully represented in the European Court of Human Rights of its pro bono client Šarūnas Narbutas, a lawyer and a patient advocate in Lithuania, who spoke out against the Lithuanian Government for its mismanagement of healthcare services for cancer patients during the Covid pandemic.
- Represented U.S.-headquartered biotech company Jounce Therapeutics, Inc. on its sale to Concentra Biosciences, LLC, an affiliate of Tang Capital Management, for $1.85 per share plus one contingent value right per share with respect to certain legacy assets of Jounce.
Slaughter and May
The extensive team at Slaughter and May addresses a variety of contentious and non-contentious matters, including commercial agreements, IP rights strategies and M&A. Duncan Blaikie and Claire Jackson jointly oversee matters. Blaikie frequently guides clients through the complexities of licensing, collaboration, and research and development agreements, while Jackson handles transactional demergers, joint ventures and inter-conditional asset swaps. IP licensing arrangements are a practice strength of Laura Houston.
Responsables de la pratique:
Duncan Blaikie; Claire Jackson
Autres avocats clés:
Laura Houston
Principaux clients
GlaxoSmithKline
Hikma
Thermo Fisher
Novo Nordisk
Bupa
GE Healthcare
Union Medical
Reckitt Benckiser
Immunocore
Oxford Nanopore
Lonza
CSL
Enara Bio
Artha Health Limited
International Finance Facility For Immunisation Company
Mylan
Illumina
Cantel Medical Corp
Varian Medical Systems
Oxford Sciences Enterprises
Bunzl
Afreximbank
Takeda
Shire Pharmaceuticals
Virgin Active
Deepmind
The Royal Marsden Cancer Charity
Orchard Therapeutics plc
AOP Health International Management AG
ELIQUENT Life Sciences
Covis Pharma
GHO Capital
Principaux dossiers
- Handled ELIQUENT Life Sciences and GHO Capital Partners LLP on ELIQUENT’s acquisition of RApport Global Strategic Services.
- Advised the Royal Marsden Cancer Charity (the charity which raises money to support The Royal Marsden on the brand-related aspects of its partnership arrangements with the Ralph Lauren brand.
Stephenson Harwood
Stephenson Harwood‘s team is skilled in addressing a range of issues for clients, including strategic collaborations, funding rounds, and life sciences M&A. The unit is led by the ‘commercially astute’ Alexandra Pygall, whose practice spans partnering agreements and IP disputes linked to partnering deals. Dan Holland has deep knowledge of clinical and commercial supply agreements. Anthony Clare is equipped to handle public and private life sciences M&A. Early-stage research, collaboration and licensing agreements are key practice strengths of Naomi Leach.
Responsables de la pratique:
Alexandra Pygall
Autres avocats clés:
Dan Holland; Anthony Clare; Naomi Leach; Rob Jacob; Tom Page; Kristian Shearsby; Michelle Gomes
Les références
‘The Stephenson Harwood life sciences team is a high-performing and knowledgeable group who follow industry trends closely and use their broad experience to advise clients appropriately.’
‘Alexandra Pygall is an excellent individual who has a very broad range of experience and interest across life sciences. She is highly skilled from a technical legal perspective but is also commercially astute and provides pragmatic advice. She works well with her junior members of staff and provides them with good client exposure. ’
‘Very dynamic, business-focused and pragmatic law firm. ’
Principaux clients
Bicycle Therapeutics
BioNTech
BenevolentAI
Flarin Holdings Limited
GlaxoSmithKline PLC
Johnson & Johnson Innovation
LifeArc
Novacyt
Oxford Biomedica (UK) Ltd
Aptamer
Futura
Principaux dossiers
- Acting on behalf of Primer Design Limited (“PD”) and its French parent company, Novacyt S.A., in defending a £134m claim brought by the Secretary of State for Health and Social Care (“DHSC”) and PD’s £81m counterclaim to recover sums due from DHSC under unpaid invoices.
- Advised UCB Ventures, BGF and 4Bio Capital, who led the over-subscribed Series A funding round of $25million in ViaNautis Bio.
- Advised Bicycle Therapeutics simultaneously on two complex collaboration and licence agreements in the radiopharm space, one with Novartis and one with Bayer, to discover and develop multiple targeted radioligand therapies in oncology. Under both deals Bicycle is eligible for payments of up to USD 1.7 billion.
Carpmaels & Ransford LLP
EPO opposition, strategic prosecution, and patent and SPC litigation are core pillars of the ‘very strong’ team at Carpmaels & Ransford LLP. David Wilson leads the firm’s dispute resolution team and has a proven track record in negotiating high-value licenses and settlement agreements. James Warner is noted for his adept handling of multi-opponent EPO opposition proceedings. IP transactions specialist Jake Marshall is singled out for his expertise in commercial agreements. Camilla Balleny frequently brings her contentious IP experience to bear on SPC and divisional filing strategies.
Responsables de la pratique:
Hugh Goodfellow; David Wilson; James Warner; Jake Marshall; Mark Chapman; Roger Lush
Autres avocats clés:
Camilla Balleny; Edward Oates; Cameron Marshall; Daniel Wise; Harvey Adams; Jennifer Antcliff; Stephen Duffield; Simon Llewellyn; Agathe Michel-de Cazotte; Daniel Goodman; Paul Kaufman; Craig Lumb; Aled Richards-Jones
Les références
‘Carpmaels has strong industry knowledge and effectively integrates their litigators and patent attorneys.’
‘Aled Richards-Jones is a rising star who has excellent strategic judgment.’
‘Very strong team. Great depth and knowledge.’
Principaux clients
Sanofi-Aventis
Johnson & Johnson group, including various Janssen entities
FibroGen, Inc.
AMO Development, LLC (part of the Johnson & Johnson group)
Novartis
Takeda
Regeneron Pharmaceuticals, Inc.
Sidley Austin
Principaux dossiers
- Instructed to help defend and enforce the patents that protect Johnson & Johnson’s biggest product, Stelara.
- Instructed by Janssen to revoke certain antibody patents (owned by Amgen) at the EPO and in the UK, to clear the way for the launch of its product, TECVAYLI.
DLA Piper
The broad offering at DLA Piper spans expertise across regulatory, transactions, product liability and patent litigation. Birmingham-based practice head Richard Taylor assists clients ranging from multinationals to public bodies on issues such as IP licensing and procurement. Also in Birmingham, Ryan Harrison excels in advising on cross-border commercial agreements. Mark Dewar’s expertise extends to advising on risk across supply chains. In Leeds, IP and commercial law specialist Kate Black is further recommended.
Responsables de la pratique:
Richard Taylor
Autres avocats clés:
Ryan Harrison; Mark Dewar; Tom Heylen; Teresa Hitchcock; Kate Black
Principaux clients
Dechra Pharmaceuticals
Cancer Research UK
Medica Group plc
Argenx
QMD (Q Medical Devices)
Anthony Nolan Trust
International Health Partners
Curasight
Pfizer
Medtronic
Sanofi
Syneos Health
Bristol Myers Squibb
ResMed
Dexcom
Takeda
Incyte
Vertex
GlaxoSmithKline
Novartis
Ipsen
Principaux dossiers
- Advising Pfizer in the UK, highlights this year including advising Pfizer on its contractual arrangements with the EU for supply of the Covid vaccine.
- Advising FTSE100 global veterinary pharmaceuticals business Dechra Pharmaceuticals on the GBP4.46bn take private backed by EQT. .
- Advised on over 30 pro bono matters opened for Cancer Research UK, continuing our close pro bono partnership with CRUK. We are particularly proud of our work this year supporting CRUK’s Bowelbabe Fund and the legacy of the late Dame Deborah James.
Hill Dickinson LLP
Medical device regulation, high-profile collaborations and strategic investments are among the areas in which the life sciences team at Hill Dickinson LLP operate. Praised for his ‘outstanding service’, practice co-chair Michael Corcoran is well versed in the alternative proteins sector. Fellow co-head Jamie Foster is expert at guiding healthtech and biotech start-ups through commercial and regulatory frameworks. Corporate healthcare specialist Monica Macheng joined in May 2023 from Bevan Brittan LLP.
Responsables de la pratique:
Jamie Foster; Michael Corcoran
Autres avocats clés:
Monica Macheng; James Paton Philip
Les références
‘Michael Corcoran has provided outstanding service.’
Principaux clients
Liverpool School of Tropical Medicine
NorthEdge Capital LLP
The Clatterbridge Cancer Centre NHS Foundation Trust
AI Sight Limited
Exhalation Technology Ltd
Zoomdoc Limited
Lakeland Laboratories Holdings Limited
The Veterinary Defence Society Limited
Centre for Process Innovation (“CPI”)
NHS Business Services Authority
Ted Jennings
Psych Capital Plc
Hydrogen Future Industries Plc
Palatine Private Equity
ITS Technology Group
Parity Medical
Touchpoint Medical
Dr Schar UK
Genflow Biosciences
The Royal Marsden NHS Foundation Trust
Unity Insight
The Royal Wolverhampton NHS Trust
Yooma Wellness Inc
PAM Occupational Health Solutions Ltd
Hilltop Leaf
Fishawack Health
Curaleaf
ADDVantage Technologies
Juvenescence Ltd
The Fertility Partnership Ltd
California Croyobank
Insilico Medicines, Inc
Agronomics Ltd
iOx Therapeutics Ltd
JD Healthcare
Lyphe Group
CME Medical Ltd
OBG Pharmaceuticals Ltd
Genus Plc
SalvaRsx Group Plc
Sinclair Pharma Plc
Port Erin Biopharma Investments
Napa Therapeutics Ltd
Sativa Investments Plc
FastForward Innovations Ltd
Thermo Electron (Management) Services Ltd
Sativa Group Plc
Principaux dossiers
- Advised Liverpool School of Tropical Medicine (LSTM) on the multi-million-pound purchase of key life science building, The Accelerator, in the city’s health campus.
- Advised private equity firm NorthEdge Capital LLP on its multi-million-pound investment into Antibody Analytics, a leading provider of immunology research services.
- Advised The Clatterbridge Cancer Centre NHS Foundation Trust on a strategic leasehold acquisition of the Rutherford Cancer Centre, Liverpool – a state of the art diagnostic centre for cancer care.
Marks & Clerk
Clients ranging from start-ups and universities to the likes of Gilead and AstraZeneca turn to the patent prosecution team at Marks & Clerk for assistance with work such as patent revocation actions, patent portfolio due diligence and EPO opposition matters. Mike Gilbert heads up the team alongside Will Nieuwenhuys. Gilbert's practice combines high-profile patent litigation and matters concerning Supplementary Protection Certificates, while Nieuwenhuys is known for his expertise in small molecule organic and pharmaceutical chemistry. Charlie Balme is equipped to handle litigation, arbitration and commercial IP matters connected to medical devices.
Responsables de la pratique:
Mike Gilbert; Will Nieuwenhuys
Autres avocats clés:
Charlie Balme; Jonathan Stafford; Will Arends; Andrea Williams; Dan McGrath; Marcus Riby-Smith; Mari Brace
Principaux clients
Pfizer
Daiichi Sankyo
Gilead Sciences
Roche
Advanced Medical Solutions
Meril Life Sciences
RevoluGen
Inside Biometrics Limited
Sumitomo Pharma America, Inc.
Menarini
Oxford Cannabinoid Technologies
Mills & Reeve LLP
Global licence agreements, collaboration agreements and fundraising mandates are among the areas of activity for the Cambridge-based life sciences team at Mills & Reeve LLP. James Fry heads the practice and has expertise in intellectual property licensing work and regulatory issues such as clinical trials. His Cambridge colleague Kevin Calder's practice centres on commercial contracts and procurement. Research and development agreements fall within the purview of Stephanie Caird's practice. Isabel Teare is a further name to note.
Responsables de la pratique:
James Fry
Autres avocats clés:
Kevin Calder; Stephanie Caird; Isabel Teare
Principaux clients
GSK
Illumina
CMR Surgical
Neurocrine Biosciences
F-star Therapeutics
Coloplast
NRG Therapeutics
PhoreMost
Instil Bio
Calypso Biotech
Sphere Fluidics
Sanger Institute
Wavebreak Therapeutics
Mission Therapeutics
Oxford Biomedica
ImmuOne
Kadans
Amano Enzyne
Rinri Therapeutics
RNAvate
Pivotal Earth
Principaux dossiers
- Advised F-star Therapeutics on its strategic discovery collaboration and licence agreement with global pharmaceutical company Takeda. Also advised F-star on its second licence agreement with Takeda for the further development of a novel next-generation immuno-oncology bispecific antibody.
- Advised Orbit Service Partners Inc., an emerging provider of innovative solutions in the field of public health, on a groundbreaking licence and collaboration agreement with Verily, an Alphabet precision health technology company based in South San Francisco, USA, to introduce the Debug programme in Barbados and the Caribbean.
- Acted for Autolus Therapeutics Limited on the grant of a lease of Nucleus, Stevenage from Forge Life Sciences (a joint venture between Reef Group and UBS). The property is a 70,000 square foot purpose built GMP manufacturing facility in Stevenage. .
Mishcon de Reya LLP
With expertise across sectors spanning pharmaceutical, medical devices and crop sciences, Mishcon de Reya LLP provides both contentious and non-contentious assistance for clients ranging from emerging companies to multinationals. Patrick Farrant leads the life sciences group and frequently advises on mandates such as IP licences, R&D agreements and spin-outs. IP disputes specialist David Rose is geared to handle trade mark and patent cases in the UK and across Europe. Gayle Curry, who joined the team following the firm’s January 2023 merger with Taylor Vinters, is notably strong on matters connected to digital health.
Responsables de la pratique:
Patrick Farrant
Autres avocats clés:
David Rose; Campbell Forsyth; Gayle Curry; Charles Fletcher; Nicola McConville; Chris Keen; Justin Lambert
Principaux clients
AccuRx
Binx Health Limited
Brookfield
Centauri Therapeutics
DIOSynVax
Dama Health
Dr Reddy Laboratories
Endomagnetics Limited
LoQus23
Luye Pharma
MatchBio Limited
Maxion
Medoron
Mestag Therapeutics
Microbiotica Limited
Nanna Therapeutics
Nucleome Therapeutics
Osstec Ltd
PetMedix
PharmEnable
Quell Therapeutics
RQ Bio
RSC
RxCelerate
Sania Therapeutics
Sanofi
T-Therapeutics
ViaNutis (previously SomaServe)
Zentiva Pharma
Principaux dossiers
- Advised RQ Bio on its strategic collaboration with AbCellera to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio.
- Acting for Dr Reddy’s Laboratories in a significant follow on cross-undertaking in damages claim against Warner-Lambert relating to pregabalin.
- Acted for Maxion Therapeutics Limited on an investment of £12,000,000 from various investors including LifeArc, Monograph Capital Partners I LP, and BGF Investment Management Limited.
Morgan, Lewis & Bockius UK LLP
Transactional, regulatory and competition work are three key strata running through the life sciences offering at Morgan, Lewis & Bockius UK LLP. Allison Soilihi co-heads the team and is well-placed to handle corporate life sciences work such as private equity transactions. Merger clearances and licensing mandates are firmly in the wheelhouse of fellow co-head Omar Shah. Paul Ranson‘s practice straddles commercial and regulatory matters, while Frances Murphy is an authority on EU and UK competition matters.
Responsables de la pratique:
Omar Shah; Allison Soilihi
Autres avocats clés:
Paul Ranson; Frances Murphy; Tim Powell
Les références
‘Personable and extremely knowledgable, the team go out of their way to ensure they understand our business.’
‘Nicholas Moore and Humphrey Thomas are responsive and proactive and provide excellent advice before, during and after a potential acquisition. They are good at managing challenging stakeholders both internally and externally. ’
‘Deep personal expertise. Ability to right-size the approach to the size of the client.’
Principaux clients
Advanz Pharma
StoneCalibre
Mercury Pharma (now owned by Advanz)
Amdipharm (now Advanz)
Focus Pharma
AstraZeneca UK
Former Focus Pharmaceuticals directors Messrs. Roland Brown, Mark Cresswell, and Graeme Duncan
AMCo Pharma
Replimune Group
RPC
The medical and life sciences team at RPC is known for its strength in product liability work, pre-marketing approval mandates and commercial and injury disputes arising from clinical trials. Described as a ‘doyenne of the field’, Dorothy Flower leads the practice. She is praised for her experience in dealing with ‘medical devices and all aspects of cosmetic surgery’. Florence Page and Emma Kislingbury provide key support to Flower.
Responsables de la pratique:
Dorothy Flower
Autres avocats clés:
Florence Page; Emma Kislingbury
Les références
‘RPC is well-regarded in the life sciences and healthcare sector. Led by Dorothy Flower, the specialised team understands the sector and has a good understanding of the context in which disputes arise and how to effectively resolve them. ’
‘Dorothy Flower is a doyenne of the field, with decades of experience in acting for life science clients and their insurers. She is adept at understanding the interplay between the underlying issues and the insurance considerations. She is particularly experienced in dealing with medical devices and all aspects of cosmetic surgery and products.’
Principaux dossiers
- Acted for an orthopaedic implant manufacturer in the large-scale metal-on-metal hip litigation in England and Wales which concluded with a judgment in favour of the manufacturers in 2018.
Squire Patton Boggs
Andrew Wilkinson leads a life sciences team at Squire Patton Boggs that is praised for its ‘strong track record of legal advice that can be applied and implemented’, and assists pharmaceutical and medical device suppliers with a range of regulatory and commercial issues, notably focusing on market access issues following on from Brexit. Jon Lent heads up the healthcare team alongside Mark Yeo. Healthcare providers turn to the unit for assistance in areas including corporate finance, employment and real estate.
Responsables de la pratique:
Andrew Wilkinson; Mark Yeo; Jon Lent
Autres avocats clés:
Adrian Spooner; Francesco Liberatore; Bradley Silver; Nicola Smith
Les références
‘A unique blend of legal knowledge and direct professional experience from working in the sector.’
‘A strong track record of legal advice that can be applied and implemented – based on the team’s deep understanding of operations within healthcare and the pharmaceutical industry.’
Principaux clients
HC-One
OakNorth Bank plc
Stevens & Bolton LLP
The ‘highly efficient, professional and approachable’ team at Stevens & Bolton LLP assists clients such as pharmaceutical and biotech companies; digital health providers; and life sciences sector trade bodies, with a slew of transactional, regulatory and IP-related work. Charlotte Tillett heads up the Guildford-based team and is active across a range of contentious and advisory IP-related matters including IP licensing and trade mark disputes. Gustaf Duhs is singled out for his in-depth knowledge of public law and governmental issues, while Michael Frisby has amassed considerable experience in leading and coordinating cross-border disputes.
Responsables de la pratique:
Charlotte Tillett
Autres avocats clés:
Michael Frisby; Gustaf Duhs; Keith Syson; Catherine Penny; Tom Collins; Beverley Flynn; Charles Maurice;
Les références
‘Very competent with a high level of responsiveness.’
‘Very knowledgeable in life science and regulatory matters.’
‘The team has been providing us with their legal expertise for many years. Their contributions and expertise in various fields are invaluable for our legal agreements and amendments. They are always quick to give their attention and support. They often assist us and participate in our meetings with customers whenever it is necessary.’
Principaux clients
Accord Healthcare
Exeltis
Fresenius Kabi SwissBioSim GmbH
Glenmark Pharmaceuticals Europe Ltd
Insud Pharma SLU
Lonza Biologics plc
MAbxience Research, SL
Mediq Healthcare UK Ltd
SecurMed UK
British Generic Manufacturers Association
Principaux dossiers
- Advising Lonza Biologics plc on key licensing aspects of the high-value, strategic acquisition of Dutch biotechnology company Synaffix.
- Advising Insud Pharma SLU on the regulation of pricing of its pharmaceutical product.
- Advising one of the key stakeholders in the development of the London Cancer Hub, an exciting new world-leading collaborative life sciences campus.
White & Case LLP
White & Case LLP is known for its ability to handle healthcare and life sciences transactions in the UK and further afield. Mike Weir is the key contact in London. He is frequently sought out by private equity houses for assistance with work such as cross-border M&A and corporate reorganisation. Additional key contacts at the firm include Ross Allardice, who frequently guides clients through funding rounds, and Lucy Bullock, who bolsters the private equity expertise at the firm and is equipped to advise sponsor-held portfolio companies on a range of transactional work.
Responsables de la pratique:
Mike Weir
Autres avocats clés:
Ross Allardice; Lucy Bullock; Lindsey Canning; James Killick ; Philip Trillmich; James Turner; James Charteris-Black
Principaux clients
Advanz Pharma
Bridgepoint/Diaverum
Pfizer
GSK PLC
Servier
European Dental Group
Karo Healthcare
Clinigen NoIK Partners/Mabtech
Klinik “Helle Mitte” GmbH Berlin
Praemia Healthcare NoCJ Bioscience
CMR Surgical
Genomics plc
Lakestar
Oaktree Capital Management/Avenga
Atomico
Takeda